StockNews.com Downgrades Aurinia Pharmaceuticals (NASDAQ:AUPH) to Buy

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a report released on Wednesday.

Aurinia Pharmaceuticals Price Performance

Shares of NASDAQ:AUPH opened at $7.99 on Wednesday. Aurinia Pharmaceuticals has a 12 month low of $4.71 and a 12 month high of $10.67. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11. The business’s 50 day simple moving average is $8.47 and its 200-day simple moving average is $7.66. The firm has a market capitalization of $1.14 billion, a price-to-earnings ratio of -53.26 and a beta of 1.22.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. SBI Securities Co. Ltd. purchased a new stake in Aurinia Pharmaceuticals in the 4th quarter valued at approximately $25,000. Tower Research Capital LLC TRC lifted its stake in Aurinia Pharmaceuticals by 368.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 2,635 shares in the last quarter. Vermillion & White Wealth Management Group LLC purchased a new stake in Aurinia Pharmaceuticals in the 4th quarter valued at approximately $31,000. Natixis purchased a new stake in Aurinia Pharmaceuticals in the 4th quarter valued at approximately $49,000. Finally, Blue Trust Inc. lifted its stake in Aurinia Pharmaceuticals by 3,041.4% in the 4th quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 6,174 shares in the last quarter. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.